Most Read Articles
Rachel Soon, 08 Apr 2020

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Roshini Claire Anthony, 27 May 2020

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates. 

Adjunctive brivaracetam safe, effective for long-term treatment of patients with epilepsy

27 Apr 2020

Long-term use of brivaracetam as an adjunctive treatment is well tolerated and effective in patients with focal seizures or primary generalized seizures (PGS), as shown in a study.

The study included patients aged ≥16 years who had completed double‐blind, placebo‐controlled adjunctive brivaracetam trials. Safety analysis involved 652 patients with focal seizures and 15 with PGS, while efficacy analysis comprised 648 and 15 patients, respectively.

Overall, 49.2 percent of patients had ≥48 months of exposure to the drug. Treatment‐emergent adverse events (TEAEs) occurred in 608 patients (91.2 percent), including 595 (91.3 percent) with focal seizures. Brivaracetam discontinuation was reported in 14.8 percent of patients due to TEAEs, in 56.7 percent due to drug‐related TEAEs, and in 22.8 percent due to serious TEAEs. Common reported TEAEs in the focal seizures group were headache (25.3 percent) and dizziness (21.9 percent).

Mean changes from baseline in anxiety and depression (measured using the Hospital Anxiety and Depression Scale) over the 2‐year evaluation period were −0.7 and −0.2, respectively.

In terms of efficacy, median reduction from baseline in focal seizure frequency per 28 days was 57.3 percent. The 50-percent responder rate was 55.6 percent, with 6‐ and 12‐month seizure freedom rates of 30.3 percent and 20.3 percent, respectively.

Efficacy outcomes improved with increasing duration of exposure to brivaracetam, with changes remaining stable through 9 years. Quality of life also improved. Mean improvement in Patient‐Weighted Quality of Life in Epilepsy Inventory total score (efficacy set) from baseline were 5.7 at month 12 and 6.5 at month 24.

The present data support the long‐term use of adjunctive brivaracetam to treat patients with focal seizures, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 08 Apr 2020

Guidelines for local pharmacists on what actions to take during the COVID-19 pandemic have been issued by the Malaysian Pharmaceutical Society (MPS).

Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Pearl Toh, 26 Sep 2019
The Singapore Health Sciences Authority (HSA) has recalled eight brands of ranitidine products containing trace amounts of the nitrosamine impurity NDMA*, which is a potential human carcinogen.
Roshini Claire Anthony, 27 May 2020

The use of a vaginal cleansing intervention prior to Caesarean delivery reduced the incidence of surgical site infections (SSIs), according to a study presented at ACOG 2020. However, the addition of intravenous (IV) azithromycin prophylaxis had no added impact on SSI rates.